1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Smith & Nephew plc

Smith & Nephew plc

SNN
Smith & Nephew plcUS flagNew York Stock Exchange
29.01
USD
+1.13
- -
12.14BMarket Cap
Smith & Nephew plc
SNN
(New York Stock Exchange)

Recent

price

29.01

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
8.92
9.58
9.22
9.66
10.34
7.7
10.66
10.89
11.24
11.75
10.44
11.9
11.69
12.74
13.31
14.22
10.34
Revenue per Share
1.39
1.29
1.61
1.23
1.12
0.68
1.79
1.75
1.52
1.37
1.03
1.2
0.5
0.6
0.94
1.44
1.12
Basic EPS, GAAP
1.93
1.89
2.01
1.92
1.53
1.71
1.94
2.49
2.13
2.67
2.14
2
1.05
1.4
2.26
2.96
1.53
Free Cash Flow per Basic Share
0.3
0.33
0.41
0.53
0.56
0.45
0.64
0.61
0.74
0.73
0.75
0.75
0.73
0.75
0.75
0.76
0.56
Dividend per Share
3.12
3.57
4.3
4.53
4.52
4.42
4.52
5.31
5.49
5.81
6.02
6.34
6.04
5.98
6.03
6.23
4.52
Book Value per Share
1.4
1.87
1.81
1.95
0.3
0.5
0.41
1.03
1.49
0.89
0.99
1.34
1.14
1.28
1.38
1.53
0.3
Tangible Book Value per Share
444
446
448
450
446
602
438
438
436
437
437
438
446
435
436
433
447
Basic Weighted Avg Shares
3,962
4,270
4,137
4,351
4,617
4,634
4,669
4,765
4,904
5,138
4,560
5,212
5,215
5,549
5,810
6,164
4,617
Sales/Revenue/Turnover
23.52
21.5
22.21
20.27
19.38
13.55
19.32
19.73
20.33
19.27
6.47
13.09
12.16
11.17
14.8
13.9
19.38
Operating Margin (%)
273
297
312
361
427
493
463
447
435
502
545
563
548
527
555
574
427
Depreciation Expense
615
575
721
556
501
410
784
767
663
600
448
524
223
263
412
625
501
Net Income, GAAP
31.28
31.63
33.97
30.67
29.83
26.65
26.18
12.74
15.11
19.25
- -
10.58
5.11
9.31
17.27
19.77
29.83
Effective Tax Rate (%)
15.52
13.47
17.43
12.78
10.85
8.85
16.79
16.1
13.52
11.68
9.82
10.05
4.28
4.74
7.09
10.14
10.85
Profit Margin (%)
1,240
1,067
1,214
1,183
1,278
1,131
1,181
1,385
1,612
1,655
2,976
2,293
2,141
1,759
2,890
2,508
1,278
Working Capital
642
16
430
347
1,666
1,434
1,564
1,423
1,301
1,975
3,353
2,848
2,712
2,319
3,258
3,177
1,666
LT Debt
2,773
3,187
3,884
4,047
4,040
3,966
3,958
4,644
4,874
5,141
5,279
5,568
5,259
5,217
5,265
5,289
4,040
Total Equity
17.9
17.15
14.94
13.52
11.98
7.97
11.65
13.62
13.27
11.53
- -
6.71
6.93
6.71
8.25
7.84
11.98
Return on Invested Capital (%)
19.79
16.98
18.49
12.98
10.46
8.15
15.09
14.11
11.63
9.77
- -
6.79
3.63
4.74
6.53
8.94
10.46
Return on Capital (%)
24.84
19.3
20.39
14.02
12.39
10.24
19.79
17.83
13.93
11.98
8.6
9.66
4.12
5.02
7.86
11.84
12.39
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'14
Sep'14
Dec'14
ST Debt
65
91
39
LT Borrowings
1,986
1,936
1,656
LT Finance Leases
- -
- -
10
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
894
894
894
Market Capitalization
31,930
30,094
32,843

Working Capital

FRC

•

in mil. unless spec.
Jun'14
Sep'14
Dec'14
Total Current Assets
2,532
2,529
2,440
Cash, Cash Equivalents & STI
140
147
93
Accounts Receivable, Net
1,207
1,173
968
Inventories
1,185
1,209
1,181
Total Current Liabilities
1,148
1,228
1,162
Payables & Accruals
- -
- -
- -
ST Debt
65
91
39
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.07%
0.1%
0.46%
Free Cash Flow
7.13%
13.92%
30.19%
Net Income, GAAP
12.65%
17.16%
51.7%
Sales/Revenue/Turnover
3.08%
6.31%
6.09%
Total Cash Common Dividend
- -
- -
0.92%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
5,549
2024
- -
- -
- -
- -
5,810
2025
- -
- -
- -
- -
6,164

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.6
2024
- -
- -
- -
- -
0.94
2025
- -
- -
- -
- -
1.44

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.75
2024
- -
- -
- -
- -
0.75
2025
- -
- -
- -
- -
0.76
Similar Companies
EKF Diagnostics Holdings plc (EKDHF)
Bonraybio Co. Ltd. (6955.TW)
Vapotherm, Inc. (VAPO)
Medcaptain Medical Technology Co. Ltd. Class H (2041.HK)
HOB Biotech Group Corp.,Ltd (688656.SS)
Nova Eye Medical Limited (ELXMF)
Business
Smith & Nephew plc is a medical technology company that develops, manufactures, markets and sells medical devices and services focused on the repair, regeneration and replacement of soft and hard tissue. The company operates through three segments: Orthopaedics, offering hip, knee and shoulder implants for joint replacement, robotics-assisted technologies including the CORI Surgical System, and trauma products such as the EVOS Plating System and AETOS Shoulder System to stabilise fractures and correct deformities; Sports Medicine & ENT, providing advanced instruments for soft tissue repair and removal, including the REGENETEN Bioinductive Implant for rotator cuff tears and extra-articular ligaments, arthroscopic enabling technologies like COBLATION wands, and ENT devices for tonsil and adenoid procedures; and Advanced Wound Management, encompassing negative pressure wound therapy systems such as RENASYS EDGE and PICO, bioactives including SANTYL and GRAFIX PLUS skin substitutes, and advanced wound care dressings like ALLEVYN LIFE. Founded in 1856 and headquartered in Watford, UK, Smith & Nephew plc conducts global operations in approximately 100 countries, targeting surgeons, nurses, physicians and healthcare institutions in established markets including the US, Europe, Japan and emerging markets. In recent developments, the company advances its 12-Point Plan transformation programme, achieving underlying revenue growth of 5.3% to $5.8 billion in 2024, trading profit margin expansion to 18.1%, free cash flow of $551 million and adjusted ROIC of 7.4%, with over 60% of growth from products launched in the past five years including CATALYSTEM Primary Hip System and CORIOGRAPH planning services; it completed the CartiHeal acquisition for the AGILI-C Cartilage Repair Implant, expanded REGENETEN indications to extra-articular ligaments in the US, launched nearly 50 new products over three years, reduced Day Sales of Inventory by 20 days, delivered 410bps in cost savings, cut restructuring costs to $123 million, reorganized around business units for greater accountability, and announced a $500 million share buyback programme commencing August 2025.

Company News

Company News APIChatGPT

  • zacks.com

    Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets

  • globenewswire.com

    Smith+Nephew lancia in Europa CARTIHEAL™ AGILI-C™, l'innovativo impianto per la riparazione della cartilagine, che sarà presentato all'ICRS Summit in Portogallo.

  • globenewswire.com

    Smith+Nephew's revolutionary CARTIHEAL™ AGILI-C™ Cartilage Repair Implant launches in Europe; to be featured at ICRS Summit in Portugal

  • globenewswire.com

    Smith+Nephew lanza en Europa el innovador implante de reparación de cartílago CARTIHEAL™ AGILI-C™, que será protagonista en el Congreso ICRS de Portugal

  • zacks.com

    Smith+Nephew Launches EVOS PELVIC System to Advance Trauma Care

  • defenseworld.net

    Smith & Nephew SNATS (NYSE:SNN) Reaches New 52-Week Low – Time to Sell?

  • globenewswire.com

    MULTIMEDIA UPDATE: Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management

  • globenewswire.com

    Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management

  • globenewswire.com

    Smith+Nephew to showcase leading shoulder technologies for joint repair and reconstruction at ICSES 2026

  • accessnewswire.com

    Smith & Nephew Plc Announces Result of Cash Tender Offer for 2030 Bonds

  • accessnewswire.com

    Smith & Nephew Plc Announces Pricing of Cash Tender Offer for 2030 Bonds

  • gurufocus.com

    Is It Too Late to Buy Smith & Nephew PLC (SNN) After 3.3% Rally? GF Value Says Undervalued

  • defenseworld.net

    Smith & Nephew SNATS (NYSE:SNN) Hits New 52-Week Low Following Analyst Downgrade

  • accessnewswire.com

    Smith & Nephew Plc Announces Cash Tender Offer for 2030 Bonds Up To $250m

  • proactiveinvestors.co.uk

    Smith & Nephew keeps Jefferies 'buy' despite H2 growth scepticism

  • proactiveinvestors.co.uk

    Panmure Liberum cuts Smith & Nephew target price after disappointing results and CFO exit

  • proactiveinvestors.co.uk

    UBS cuts Smith & Nephew target on competitive threats to three franchises

  • defenseworld.net

    BlackRock Inc. Invests $505.32 Million in Smith & Nephew SNATS, Inc. $SNN

  • zacks.com

    SNN Advances Surgical Robotics Through Imperial College Partnership

  • proactiveinvestors.co.uk

    Smith & Nephew shares slip on CFO's departure